Report Library
View More
Sjögren’s Disease KOL Interview - N...
April 28, 2025
Datamonitor Healthcare I&I: Dry Eye...
April 28, 2025
Datamonitor Healthcare Oncology: Wa...
April 18, 2025
Datamonitor Healthcare Oncology: Ut...
April 18, 2025
Datamonitor Healthcare Infectious D...
April 18, 2025
2024 Deal-making Roundup
April 17, 2025
Datamonitor Healthcare I&I: Primary...
April 17, 2025
Datamonitor Healthcare CV&Met: Duch...
April 17, 2025
Head and Neck Cancer Awareness Mont...
April 10, 2025
Targeting HER3 in EGFR TKI-resistan...
April 10, 2025
Wet Age-Related Macular Degeneratio...
May 12, 2025
2025 Biomedtracker Datamonitor Hea...
May 8, 2025
Wet AMD KOL- France
May 8, 2025
Datamonitor Healthcare Oncology: NH...
May 8, 2025
Wet AMD KOL- US, South
May 7, 2025
Datamonitor Healthcare Infectious D...
May 6, 2025
Datamonitor Healthcare CV&Met: Sick...
May 6, 2025
Datamonitor Healthcare I&I: Heredit...
May 1, 2025
Podcast: Highlights from AAN 2025
April 30, 2025
Sjögren’s Disease Full Report Avail...
April 30, 2025
Sjögren’s Disease KOL Interview - N...
April 28, 2025
Datamonitor Healthcare I&I: Dry Eye...
April 28, 2025
Datamonitor Healthcare Oncology: Wa...
April 18, 2025
Datamonitor Healthcare Oncology: Ut...
April 18, 2025
Datamonitor Healthcare Infectious D...
April 18, 2025
2024 Deal-making Roundup
April 17, 2025
Datamonitor Healthcare I&I: Primary...
April 17, 2025
Datamonitor Healthcare CV&Met: Duch...
April 17, 2025
Head and Neck Cancer Awareness Mont...
April 10, 2025
Targeting HER3 in EGFR TKI-resistan...
April 10, 2025
Wet Age-Related Macular Degeneratio...
May 12, 2025
2025 Biomedtracker Datamonitor Hea...
May 8, 2025
Wet AMD KOL- France
May 8, 2025
Datamonitor Healthcare Oncology: NH...
May 8, 2025
Wet AMD KOL- US, South
May 7, 2025
Datamonitor Healthcare Infectious D...
May 6, 2025
Datamonitor Healthcare CV&Met: Sick...
May 6, 2025
Datamonitor Healthcare I&I: Heredit...
May 1, 2025
Podcast: Highlights from AAN 2025
April 30, 2025
Sjögren’s Disease Full Report Avail...
April 30, 2025
Impact Events
More| Date | Lead Company | Event | Type | Approval Change | Approval Likelihood |
|---|---|---|---|---|---|
| 5/9/25 | Alnylam (ALNY) | VIR-2218 for Hepatitis B (HBV) Treatment (Antiviral) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/7/25 | Daiichi (4568) | Enhertu for HER2+ Breast Cancer | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/4/25 | Sylentis | SYL1801 for Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology) | Subscribers Only | Subscribers Only | Subscribers Only |
| 5/1/25 | Genmab (GMAB) | Epkinly for Follicular Lymphoma (FL) | Subscribers Only | Subscribers Only | Subscribers Only |
| 4/30/25 | GSK (GSK) | Nucala Liquid Formulation for Chronic Obstructive Pulmonary Disease (COPD) | Subscribers Only | Subscribers Only | Subscribers Only |
Upcoming Catalysts
More| Expected Date Range | Lead Company | Drug | Expected Catalyst |
|---|---|---|---|
| 04/01/2025 | Subscribers Only | Subscribers Only | Company - Divestment/Spinoff |
| 04/05/2025 | Subscribers Only | Subscribers Only | Trial Data - Other |
| 04/24/2025 | Subscribers Only | Subscribers Only | Company - Analyst/R&D Update |
| 05/09/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |
| 05/10/2025 | Subscribers Only | Subscribers Only | Trial Data - Updated Results |